General Surgery Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, 11311, Egypt.
Obes Surg. 2020 Jan;30(1):87-95. doi: 10.1007/s11695-019-04118-6.
Nonalcoholic fatty liver disease (NAFLD) is viewed as the hepatic manifestation of the metabolic syndrome with hepatic fatty infiltration is the common liver pathology. NAFLD can lead to nonalcoholic steatohepatitis (NASH), liver cirrhosis, liver cell failure, and liver malignancy.The present work aims to prospectively study the histological changes that occur in NAFLD obese patients 1-year post-laparoscopic sleeve gastrectomy (LSG) based on standardized NAS (NAFLD activity score).
This prospective study included 94 obese patients who underwent laparoscopic sleeve gastrectomy. Intraoperative wedge liver biopsy was taken from all patients with a follow-up liver biopsy at 12 months after the operation.
LSG produced a marked reduction in body weight with a mean reduction in BMI from 44.54 + 5.45 to 34.23 + 2.66 kg/m at 12 months. There were statistically highly significant improvements regarding metabolic comorbidities, blood pressure, lipid profile, and HbA1C at 12-month post-LSG (P < 0.001). The current study showed a highly statistically significant improvement at 1-year post LSG regarding steatosis grade, hepatocyte ballooning, lobular inflammation as well as fibrosis stage (P < 0.001). Moreover, the present study showed that NAS score significantly decreased from 5.20 + 1.96 at baseline to 2.63 + 1.55 at 1-year follow-up (P < 0.001).
Our relatively large patient cohort shows a significant improvement of steatosis, steatohepatitis, and fibrosis at a 1-year follow-up. LSG can lead to resolution of NAFLD, and it may be in the near future another routine indication for bariatric surgery.
非酒精性脂肪性肝病(NAFLD)被视为代谢综合征的肝脏表现,肝脂肪浸润是常见的肝脏病理。NAFLD 可导致非酒精性脂肪性肝炎(NASH)、肝硬化、肝衰竭和肝癌。本研究旨在前瞻性研究肥胖患者在腹腔镜袖状胃切除术后 1 年发生的组织学变化,基于标准化的 NAS(NAFLD 活动评分)。
这项前瞻性研究纳入了 94 例接受腹腔镜袖状胃切除术的肥胖患者。所有患者均在术中进行肝楔形活检,并在术后 12 个月进行随访肝活检。
LSG 显著降低了体重,BMI 从 44.54±5.45 降至 34.23±2.66kg/m²,12 个月时差异有统计学意义。LSG 术后 12 个月代谢合并症、血压、血脂谱和 HbA1C 均有显著改善(P<0.001)。本研究显示,LSG 术后 1 年,肝脂肪变性程度、肝细胞气球样变、肝小叶炎症和纤维化分期均有显著改善(P<0.001)。此外,本研究显示,NAS 评分从基线时的 5.20±1.96 显著降低至 1 年随访时的 2.63±1.55(P<0.001)。
我们的大样本队列研究显示,患者在术后 1 年时肝脂肪变性、脂肪性肝炎和纤维化均有显著改善。LSG 可导致 NAFLD 缓解,在不久的将来可能成为减重手术的另一个常规适应证。